Home Link
  • Sign up for free
  • Log in to your account
  • Upload for free
  • Upload for free
  • Listen
    • Live now
    • Genres
    • Trending
    • Community
    • Premium for listeners
    • Unlimited replaysPlay shows as many times as you like
    • Offline listeningDownload shows and listen on the go
    • No adsEnjoy uninterrupted listening
    • Upfront tracklistsSee the full tracklist from the start
  • Creator tools
    • Pro for creators
    • Unlimited uploadsShare infinite shows and tracks
    • Live streamingBroadcast music without takedowns
    • HQ audioEnhance the quality of your uploads
    • MonetizationMake money with Tips & Subscriptions
    • StatsUse listener insights to up your game
    • Host taggingPublish one show to multiple profiles
    • CustomizationPersonalize your profile
    • PostsSend direct messages to your fans
    • Upgrade
    • Pro for CreatorsUpload unlimited shows and live stream without takedowns.
      when paid annually,
    • Premium for listenersListen to your favorite DJs and shows offline and without limits.
  • Appearance
    • Blog
    • Terms of use
    • Support
    • Privacy policy
    • About us
    • Jobs
    • Developers
  • HomeLive nowGenresTrendingLibraryPro for creatorsPremium for Listeners

    Nivolumab

    Get the Mixcloud app

    App StoreGoogle Play Store
    • Blog
    • Terms of use
    • Support
    • Privacy policy
    • About us
    • Jobs
    • Developers

    Partners

    • TrackdropMusic promotion
    • EncoreGig bookings

    Popular

    Latest
    Advances in cancer drug development: The Lancet Oncology: March 18, 2015
    Listen to The Lancet Oncology
    11 years ago
    Advances in cancer drug development: The Lancet Oncology: March 18, 2015

    cancer treatment

    melanoma

    oncology

    nivolumab

    pembrolizumab

    +5
    +5
    +4
    +4
    +3
    +3
    +2
    +2
    +1

    cancer treatment

    melanoma

    oncology

    nivolumab

    pembrolizumab

    +5
    +5
    +4
    +4
    +3
    +3
    +2
    +2
    +1
    Nivolumab: Promising Survival Signal Coupled with Limited Toxicity Raises Expectations
    Journal of Clinical Oncology P
    12 years ago
    Nivolumab: Promising Survival Signal Coupled with Limited Toxicity Raises Expectations

    immunotherapy

    ipilimumab

    nivolumab

    immunogenicintensification

    +4
    +4
    +3
    +3
    +2
    +2
    +2
    +1

    immunotherapy

    ipilimumab

    nivolumab

    immunogenicintensification

    +4
    +4
    +3
    +3
    +2
    +2
    +2
    +1
    FirstWord Pharmaceutical News for Friday, May 17, 2013
    Track
    FirstWord Pharmaceutical News
    13 years ago
    FirstWord Pharmaceutical News for Friday, May 17, 2013

    bristol-myers squibb

    nivolumab

    astrazeneca

    roche

    novartis

    +5
    +5
    +4
    +4
    +3
    +3
    +3
    +2
    11:52

    bristol-myers squibb

    nivolumab

    astrazeneca

    roche

    novartis

    +5
    +5
    +4
    +4
    +3
    +3
    +3
    +2
    Australia signs off on Keytruda alternative Nivolumab
    Track
    RNZ: Checkpoint
    10 years ago
    Australia signs off on Keytruda alternative Nivolumab

    health

    keyrtruda

    nivolumab

    cancer

    cancer treatment

    +4
    +4
    +4
    +3
    +3
    +2
    +2
    +1
    06:52

    health

    keyrtruda

    nivolumab

    cancer

    cancer treatment

    +4
    +4
    +4
    +3
    +3
    +2
    +2
    +1
    Advanced melanoma patient receives Keytruda infusion
    Track
    RNZ: Checkpoint
    10 years ago
    Advanced melanoma patient receives Keytruda infusion

    health

    keytruda

    nivolumab

    opdivo

    immunotherapy treatments

    +4
    +4
    +3
    +3
    +3
    +2
    +2
    +1
    05:16

    health

    keytruda

    nivolumab

    opdivo

    immunotherapy treatments

    +4
    +4
    +3
    +3
    +3
    +2
    +2
    +1
    There is no more content to load